Department of Dermatology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakaecho, Itabashi, Tokyo, 173-0015, Japan.
Drugs Aging. 2020 Mar;37(3):149-160. doi: 10.1007/s40266-020-00750-5.
Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and age-specific factors of older patients must be considered. As in other age groups, regular application of moisturizers in combination with topical corticosteroids and calcineurin inhibitors, adjunctive administration of oral antihistamines/anti-allergic drugs, and avoidance of exacerbating factors comprise basic treatments for elderly AD. For moderate-to-severe cases and/or in those with a decreased ability to use topical treatments, powerful anti-inflammatory treatments may become necessary as additional treatment options. While low-dose oral corticosteroids may be useful for cases of elderly AD, careful attention should be paid to adverse effects. Oral cyclosporine (ciclosporin) is less commonly used due to the increased risk of malignancy and organ toxicity in older patients with AD. Narrow-band ultraviolet B phototherapy may also be useful for older patients, although the necessity of frequent hospital visits for irradiation therapy may become a burden of disease for such patients. As a biologic, dupilumab therapy markedly improves skin lesions and itch in older patients with AD, with a rapid response and non-serious adverse effects. Nevertheless, injection pain, expensive medical care, and regular follow-up every 2 weeks are disadvantages of dupilumab therapy. Therefore, clinicians must prioritize individualized treatment options that will reduce the burden of disease for cases of elderly AD.
特应性皮炎(AD)在老年人(老年 AD)中最近出现了一个新的亚组。在选择治疗方案时,必须考虑老年 AD 的临床特征和老年患者的年龄特异性因素。与其他年龄组一样,常规使用保湿剂联合外用皮质类固醇和钙调神经磷酸酶抑制剂、辅助给予口服抗组胺药/抗过敏药物以及避免加重因素是老年 AD 的基本治疗方法。对于中重度病例和/或外用治疗能力下降的患者,可能需要额外的强效抗炎治疗。虽然低剂量口服皮质类固醇可能对老年 AD 病例有用,但应注意不良反应。由于 AD 老年患者发生恶性肿瘤和器官毒性的风险增加,环孢素(环孢菌素)口服制剂的使用较少。窄谱中波紫外线光疗也可能对老年患者有用,尽管频繁到医院进行辐照治疗可能会给这些患者带来疾病负担。作为一种生物制剂,度普利尤单抗治疗可显著改善老年 AD 患者的皮肤病变和瘙痒,起效迅速,不良反应非严重。然而,注射疼痛、昂贵的医疗费用和每 2 周定期随访是度普利尤单抗治疗的缺点。因此,临床医生必须优先考虑个体化的治疗方案,以减轻老年 AD 病例的疾病负担。